Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 result for eluxadoline

  1. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

    We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.